New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A4938

Introduced
10/21/24  

Caption

Provides health care practitioners discretion to determine which medical conditions could qualify patients for use of medical cannabis.

Impact

With the passing of A4938, health care practitioners will enjoy increased autonomy in deciding qualifying medical conditions for cannabis use. This change is expected to enhance patient care by allowing the personalization of treatment plans, particularly for those patients who may suffer from conditions that previously were not listed but may benefit from cannabis for therapeutic or palliative purposes. This flexibility could potentially lead to improved health outcomes for patients who qualify based on their unique medical situations.

Summary

Assembly Bill A4938 amends the current law surrounding medical cannabis use in New Jersey, specifically the Jake Honig Compassionate Use Medical Cannabis Act. The bill grants health care practitioners the discretion to determine which medical conditions may qualify a patient for the use of medical cannabis, expanding the list of qualifying conditions beyond existing definitions. Under current law, patients can only qualify based on a narrow list of conditions. This bill seeks to give practitioners more flexibility in authorizing cannabis usage based on their professional judgment regarding a patient’s needs.

Contention

Some concerns have been raised regarding the broader discretion given to healthcare providers under A4938, including fears of inconsistent applications between practitioners, which may lead to disparities in access to medical cannabis. Additionally, there are apprehensions regarding how this expansion of qualifying conditions might affect regulation and monitoring efforts by state authorities. Proponents argue that the bill encourages a more patient-centered approach, while critics emphasize the need for clear guidelines to prevent misuse of the expanded definitions.

Companion Bills

NJ S3484

Same As Provides health care practitioners discretion to determine which medical conditions could qualify patients for use of medical cannabis.

Previously Filed As

NJ S3484

Provides health care practitioners discretion to determine which medical conditions could qualify patients for use of medical cannabis.

NJ A4944

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S3394

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S2392

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ A913

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S342

Authorizes home cultivation of medical cannabis.

NJ A997

Authorizes home cultivation of medical cannabis.

NJ A846

Authorizes home cultivation of medical cannabis.

NJ S1393

Authorizes home cultivation of medical cannabis.

NJ S782

Establishes program to subsidize purchase price of medical cannabis for registered qualifying patients enrolled in Medicaid or NJ FamilyCare programs.

Similar Bills

NJ A4944

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S3394

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ A913

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S2392

Authorizes medical cannabis for treatment of sickle cell anemia.

NJ S3484

Provides health care practitioners discretion to determine which medical conditions could qualify patients for use of medical cannabis.

NJ A997

Authorizes home cultivation of medical cannabis.

NJ S342

Authorizes home cultivation of medical cannabis.

NJ A846

Authorizes home cultivation of medical cannabis.